Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan vs Atenolol for Exaggerated BP Response to Exercise
NCT01736488Phase 4Completed
- Sponsor
- Boryung
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fimasartan in hypertension (HTN) (2 arms), sponsored by Boryung. Primary endpoint: Difference of sitting Systolic Blood Pressure (SiSBP) between peak exercise and resting at 8 weeks. Started Oct 2012; status: completed.
02
Drugs
fimasartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT01736488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736488.